An early cost analysis of magnetic bone growth stimulation in England

ABSTRACT

Background

Fracture nonunions impact on morbidity and health care costs and are associated with substantial pain, reduced mobility, prolonged morbidity, and a lower quality of life. CMF OrthoLogic 1000 (OL1000) is a bone growth stimulator used to promote fracture healing potentially reducing the need for surgical intervention. A cost analysis comparing CMF OL1000 versus surgical care for patients with nonunion tibial fractures was conducted.

Methods

A Markov model was developed to compare the difference in costs between CMF OL1000 versus surgical care within the English National Health Service over a 2-year time horizon. The effectiveness of CMF OL1000 was based on recently published registry data. Cost data were derived from published sources and national cost databases. Sensitivity and scenario analyses were conducted.

Results

The use of CMF OL1000 is estimated to lead to cost-savings of £1,104 per patient, a reduction in average healing time of 2.1 months and a relative risk of infection of 0.19 compared to immediate surgical intervention (standard of care). The results of the model are robust to most changes in input parameters and scenarios considered.

Conclusions

This early analysis shows cost-savings for CMF OL1000 compared with surgical intervention for individuals with nonunion tibial fractures.

KEYWORDS:

• CMF orthologic 1000
• cost analysis
• economic analysis
• magnetic bone growth stimulation
• nonunion
• tibia fracture

Author contributions

Joel Russell and Michelle Green designed and built the model with input from all other authors. All authors contributed to the drafting of the paper which was reviewed and signed off by Mohit Bhandari.

Declaration of interest

Joel Russell’s employer received funding from DJO Global for this study. Sheila Sprague reports employment from Global Research Solutions, outside the submitted work. Sam Harper's employer received funding from DJO Global for this study. Michelle Green’s employer received funding from DJO Global for this study. Mohit Bhandari reports grants and personal fees from Sanofi Aventis, personal fees from Pendopharm, grants from DJ Orthopaedics, grants and personal fees from Ferring Pharmaceuticals, grants from Anika, Flexion, Acumed outside the submitted work.

Reviewers disclosure

A reviewer on this manuscript has disclosed working for an HEOR consulting firm. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.

Supplementary material

Supplemental data for this article can be accessed here.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

DJO Global